Rubius Therapeutics emerges from stealth mode with a bang
Rubius Therapeutics is built around novel technology to grow erythrocytes in culture from hematopoietic stem cells, and genetically modify them so the mature red cells produce proteins of interest on their surface or in their cytoplasm. Jeff crafted a company narrative, media pitch, and media strategy to enable this exciting new modality to reach as wide an audience as possible in the trade press and general media. He coached founding CEO Avak Kahvejian on handling tricky questions and explaining Rubius’ breakthrough technology to lay audiences.
Rubius garnered numerous headlines upon launch. And then the coverage continued for several months, as publications throughout the life science ecosystem picked up on Rubius’ fascinating story.